Morningstar® Stock Report™

Roche Holding AG ROG

Último Precio
222.10
Cambio del día
0.00|0.00%

a 19/04/2024
17:30:13 CEST | CHF  Retraso mínimo: 15 minutos

Bid/OffersRango del DíaVolumen90d Ave VolCapitalización
221.80 - 223.90218.50 - 222.101,363,5311,417,210178.80Bil
Último Cierre52 Week RangeP/UDividendo %ISIN
222.10217.00 - 293.5515.374.36CH0012032048

Cotización Roche Holding AG

Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Cuentas Financieras
202120222023
Más...
Cuenta de Resultados
Ingresos62,801.0063,281.0060,441.00
Resultado Operativo18,155.0017,476.0015,395.00
Resultado Neto13,930.0012,421.0011,498.00
Beneficio Básico por Acción16.3815.5214.40
Num Medio Acciones diluidas en circulación860808804
Balance
Activo Corriente35,627.0033,816.0033,446.00
Activos no corrientes56,690.0054,335.0057,022.00
Total Activo 92,317.0088,151.0090,468.00
Pasivo corriente38,416.0027,239.0024,824.00
Total Pasivo---
Capital Total24,489.0027,992.0029,315.00
Flujo de Caja
Flujo de caja operativo20,976.0018,415.0016,095.00
Inversiones de Capital-4,549.00-4,552.00-4,649.00
Flujo de Caja Libre16,427.0013,863.0011,446.00

En millones, excepto "EPS básico". La moneda es CHF.

Perfil de la compañía

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Sector

Atención sanitaria

Industria

Fabricante de Medicamentos - General

Estilo de acciones

Grande-Mixto

Fin Ejercicio Fiscal

diciembre

Empleados

103,605
Principales Características
Más...
Precio/Beneficio 12 m15.42
Precio/Valor contable6.04
Precio/Ventas TTM2.98
Crec Ingresos (media 3 a)1.20
Crec BPA (media 3 a)-
Margen operativo25.47
Margen neto19.02
ROE 12 m40.13
Deuda/Fondos propios0.89
Dividendos
AntÚltimo
Fecha declarada02/02/2301/02/24
Ex-Div16/03/2314/03/24
Pagado20/03/2318/03/24
Cantidad9.509.60
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures